Enzymatic Protein Bioconjugation Platform for Site-Specific Attachment of Diverse Functional Groups and Amino Acids

Background

Protein bioconjugation is a foundational technique in biotechnology, chemical biology, and pharmaceutical development, enabling the covalent attachment of functional molecules to proteins for applications such as imaging, therapeutics, and diagnostics. The ability to site-specifically modify proteins with diverse chemical groups is crucial for creating antibody-drug conjugates, biosensors, and engineered enzymes. As the demand for more sophisticated protein-based tools and therapeutics grows, so does the need for reliable, efficient, and minimally disruptive methods to introduce non-natural functionalities into proteins. This has driven significant research into developing new bioconjugation strategies that can operate under mild conditions, maintain protein function, and provide precise control over modification sites.

Current approaches to protein bioconjugation, such as chemical modification of native amino acids (e.g., lysine or cysteine residues) or genetic code expansion to incorporate non-canonical amino acids during translation, face several limitations. Chemical methods often result in heterogeneous products due to the abundance of target residues and lack of site specificity, which can compromise protein activity and complicate downstream applications. Genetic code expansion, while offering site-specificity, requires complex engineering of the translation machinery, is limited in the types of non-canonical amino acids that can be incorporated, and often suffers from low yields and high costs. Additionally, many enzymatic tagging systems require large recognition sequences that can disrupt protein structure or function, and may not accommodate a broad range of chemical functionalities. These challenges highlight the need for new bioconjugation platforms that combine high specificity, efficiency, minimal sequence perturbation, and broad substrate compatibility.

Technology

This technology is a protein bioconjugation platform that leverages the ATP-dependent bacterial ligase RimK to achieve site-specific, covalent attachment of non-canonical amino acids (ncAAs) to proteins. The system operates by fusing a minimal, four-residue peptide tag (Asp-Ser-Glu-Glu, or DSEE) to the C-terminus of a target protein, which is then recognized by RimK. Under mild, room-temperature conditions in a pH 9 HEPES buffer with magnesium chloride, RimK catalyzes the ligation of a wide variety of ncAAs—such as those bearing alkynes, azides, alkyl halides, or diazirines—directly to the tagged protein. The enzyme also accommodates monomers with backbone variations, including beta-amino acids and thiol acids, which enables further chemical transformations like native chemical ligation and peptide macrocyclization. This approach allows for high-yield, irreversible modification with minimal disruption to protein structure, making it suitable for applications ranging from antibody-drug conjugates to fluorescently labeled proteins.

What differentiates this technology is its combination of efficiency, specificity, and versatility, achieved through the use of a short, genetically encoded tag and a naturally occurring enzyme. Unlike genetic code expansion or other bioconjugation methods that often require large tags, complex reagents, or harsh conditions, this system uses a minimal four-amino-acid sequence that is unlikely to interfere with protein function. RimK’s broad substrate scope allows for the attachment of a diverse array of functional groups and backbone-modified amino acids, expanding the chemical diversity of proteins beyond what is possible with ribosomal translation. The process is cost-effective, scalable, and compatible with standard molecular biology workflows, and can be further tailored through enzyme engineering or host strain selection. These features collectively make the platform a powerful and accessible tool for site-specific protein modification in research, biotechnology, and pharmaceutical development.

Benefits

• Enables site-specific, irreversible covalent attachment of diverse non-canonical amino acids to proteins using a minimal four-residue peptide tag.
• Supports a broad substrate scope including functional groups (alkynes, azides, alkyl halides, diazirines) and backbone variations (beta-amino acids, thiol acids), facilitating versatile downstream chemical modifications.
• Operates efficiently under mild, room-temperature conditions with low catalyst loading, suitable for large-scale protein labeling.
• Minimal structural disruption to target proteins due to the short recognition tag, preserving protein function.
• Offers higher specificity, yield, and efficiency compared to genetic code expansion methods.
• Uses cost-effective, widely available reagents and standard molecular biology techniques for easy implementation.
• Applicable to pharmaceuticals (e.g., antibody-drug conjugates), biotechnology (e.g., fluorescent labeling), and materials science.
• Allows enzyme and substrate engineering to optimize activity and prevent unwanted modifications, enhancing flexibility and customization.

Applications

• Antibody-drug conjugate production
• Site-specific fluorescent protein labeling
• Cyclic peptide pharmaceutical synthesis
• Protein immobilization for biosensors
• Photoproximity labeling for proteomics

Additional info

The system uses ATP-dependent bacterial ligase RimK to catalyze site-specific ligation of non-canonical amino acids to a C-terminal Asp-Ser-Glu-Glu (DSEE) tag. In pH 9 HEPES buffer, the reaction covalently attaches functional groups—like azides, alkynes, and thiol acids—to proteins. This method enables high-yield, irreversible bioconjugation and macrocyclization with minimal structural disruption, providing a versatile platform for creating antibody-drug conjugates and functionalized proteins.